Tumor Necrosis Factor Blocker [EPC]

859175 reported adverse events

Drugs of this class: ADALIMUMAB-ATTO INFLIXIMAB ADALIMUMAB ADALIMUMAB-ADAZ GOLIMUMAB ADALIMUMAB-AQVH ADALIMUMAB-BWWD CERTOLIZUMAB PEGOL ETANERCEPT INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

#	Side effect	Count
0	DRUG INEFFECTIVE	101856
1	INJECTION SITE PAIN	58454
2	OFF LABEL USE	57813
3	ARTHRALGIA	57481
4	PAIN	52043
5	RHEUMATOID ARTHRITIS	50219
6	INJECTION SITE ERYTHEMA	41723
7	FATIGUE	39532
8	CONDITION AGGRAVATED	35464
9	HEADACHE	31683

See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	HUMAN ANTICHIMERIC ANTIBODY POSITIVE	294	0.9735
1	INJECTION SITE RECALL REACTION	484	0.9719
2	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE	3578	0.9325
3	SWOLLEN JOINT COUNT INCREASED	940	0.8978
4	RHEUMATOID FACTOR POSITIVE	3039	0.8748
5	RED BLOOD CELL SEDIMENTATION RATE ABNORMAL	1726	0.8366
6	RHEUMATIC FEVER	1175	0.8200
7	PEMPHIGUS	6350	0.7995
8	C-REACTIVE PROTEIN ABNORMAL	3048	0.7787
9	HAND DEFORMITY	6443	0.7264

See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]